Tamoxifen-induced submassive hepatic necrosis

Cancer Journal

Volumn 6, Issue 2, 2000, Pages 58-60

  Storen, E C ^a,b   Hay, J E ^a   Kaur, J ^a   Zahasky, K ^a   Hartmann, L ^a  

^a MAYO CLINIC   (United States)

^b ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LIVER NECROSIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MIDDLE AGED; NECROSIS; TAMOXIFEN;

EID: 0033913278     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fisher B, Constantino J, Redmond C et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of node-positive breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the NSABP B-16. J Clin Oncol 1990;8:1005.
2. Tormey, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [see comments]. J Natl Cancer Inst 1993;88:1828-1833.
3. Baum M. Nolvadex Adjuvant Trial Organization: controlled trial of tamoxifen as single adjuvant therapy in management of early breast cancer: analysis of six years. Lancet 1985;1:836-839.
4. Pavlidis NA, Petris C, Briassoulis E et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients. Cancer 1992;69:2961.
5. Ogawa Y, Murata Y, Nishioka A et al. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998;351:725.
6. Maruyama S, Hirayama C, Abe J et al. Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur therapy. Dig Dis Sci 1995;40:2602.
7. Loomus GN, Aneja P, Bora RA. A case of peliosis hepatitis in association with tamoxifen therapy. Am J Clin Pathol 1983;80:881.
8. Pinto HC, Baptista A, Camilo ME et al. Tamoxifen-associated steatohepatitis - report of three cases. J Hepatol 1995;23:95.
9. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis [letter]. Ann Intern Med 1995;123:236.
10. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995;124:855.
11. Stearns V, Gelman EP. Does tamoxifen cause cancer in humans? J Clin Oncol 1998;16:779-792.
12. Fisher B et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
13. Carthew P, Nolan BM, Edwards RE et al. The role of cell death and cell proliferation in the promotion of rat tumours by tamoxifen. Cancer Lett 1996;106:163-169.
14. Riippa P. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma. Anticancer Res 1984;4:109-112.
15. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996;16:343-348.
16. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996;80:1147-1166.